相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL
Keenan T. Hartert et al.
LEUKEMIA (2021)
Dual-Targeting Peptide-Guided Approach for Precision Delivery and Cancer Monitoring by Using a Safe Upconversion Nanoplatform
Shuai Zha et al.
ADVANCED SCIENCE (2021)
Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds
Haiyan Wang et al.
SCIENCE ADVANCES (2021)
Precision Medicine in DLBCL: Are We There Yet?
Andrew J. Davies
JOURNAL OF CLINICAL ONCOLOGY (2021)
Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle
Yool Lee et al.
SCIENCE ADVANCES (2021)
The immunological and metabolic landscape in primary and metastatic liver cancer
Xin Li et al.
NATURE REVIEWS CANCER (2021)
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical significance of MUC4 isoforms in pancreatic cancer patients.
Christopher M Thompson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Temporal Multiplexed in Vivo Upconversion Imaging
Hui Li et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Lenalidomide: A Review in Previously Treated Follicular Lymphoma
Hannah A. Blair
DRUGS (2020)
Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma
Mendel Goldfinger et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
Yuan Xiao Zhu et al.
BLOOD CANCER JOURNAL (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
Christian Hurtz et al.
GENES & DEVELOPMENT (2019)
BCL6 as a therapeutic target for lymphoma
Rebecca J. Leeman-Neill et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Novel molecular classifications of DLBCL
Sydney Dubois et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma
Matija Snuderl et al.
NATURE COMMUNICATIONS (2018)
Carfilzomib weekly 20/56mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.
Valentine Richez et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Revisiting IL-2: Biology and therapeutic prospects
Abul K. Abbas et al.
SCIENCE IMMUNOLOGY (2018)
The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer
Olga Lancho et al.
TRENDS IN CANCER (2018)
A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
Anas Younes et al.
BLOOD (2018)
Immunogenomic Landscape of Hematological Malignancies
Olli Dufva et al.
BLOOD (2018)
Update on the role of lenalidomide in patients with multiple myeloma
Sarah A. Holstein et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis
Jiexian Ma et al.
EBIOMEDICINE (2017)
Perspectives for Upconverting Nanoparticles
Stefan Wilhelm
ACS NANO (2017)
Intravascular Survival and Extravasation of Tumor Cells
Boris Strilic et al.
CANCER CELL (2017)
Imaging of anticancer drug action in single cells
Miles A. Miller et al.
NATURE REVIEWS CANCER (2017)
Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation
Uri Soiberman et al.
BIOMATERIALS (2017)
HLA-C Downmodulation by HIV-1 Vpu
Edward Barker et al.
CELL HOST & MICROBE (2016)
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Richard J. Jones et al.
CLINICAL CANCER RESEARCH (2016)
An essential role for the IL-2 receptor in Treg cell function
Takatoshi Chinen et al.
NATURE IMMUNOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Patrizia Mondello et al.
ONCOLOGIST (2016)
The Effect of Lenalidomide on Multiple Myeloma Associated Macrophages
Noam Benyamini et al.
BLOOD (2016)
Identification of a novel human mitochondrial endo-/exonuclease Ddk1/c20orf72 necessary for maintenance of proper 7S DNA levels
Roman J. Szczesny et al.
NUCLEIC ACIDS RESEARCH (2013)
Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications
Richard Julian Jones et al.
BLOOD (2013)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype
Francisco J. Hernandez-Ilizaliturri et al.
CANCER (2011)
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Leandro C. Cerchietti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2010)
分享论文
